Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 3/20 | 0.40 |
| ▸ | CCR2 | P41597 | 3/20 | 0.35 |
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.35 |
| ▸ | GNAO1 | P09471 | 9/20 | 0.35 |
| ▸ | GNAI3 | P08754 | 8/20 | 0.35 |
| ▸ | GNAI1 | P63096 | 8/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24449512 | 1.00 | PRCP (0.40) | PRCPCCR2CCR1CCR5CXCR4 | |
| SCHEMBL22020922 | 1.00 | PRCP (0.40) | PRCPCCR2CCR1CCR5CXCR4 | |
| SCHEMBL21191744 | 1.00 | PRCP (0.40) | PRCPCCR2CCR1CCR5CXCR4 | |
| SCHEMBL18823467 | 1.00 | PRCP (0.40) | PRCPCCR2CCR1CCR5CXCR4 | |
| SCHEMBL19627720 | 0.98 | PRCP (0.39) | PRCPCCR2CCR1CCR5CXCR4 | |
| SCHEMBL22024596 | 0.93 | CCR2 (0.38) | PRCPCCR2CCR1CCR5CXCR4 | |
| SCHEMBL19627516 | 0.93 | PRCP (0.35) | PRCPGNAO1GNAI3GNAI1 | |
| SCHEMBL21191705 | 0.91 | CCR2 (0.37) | PRCPCCR2CCR1CCR5CXCR4 | |
| SCHEMBL25978366 | 0.91 | PRCP (0.39) | PRCPCCR2CCR1CCR5CXCR4 | |
| SCHEMBL22023785 | 0.89 | PRCP (0.33) | PRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | Epizyme, Inc. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20200113901-A1 | METHODS OF USING EHMT2 INHIBITORS | Epizyme, Inc. | 2020-04-16 | — | — | US | disclosed |
| US-20200054635-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | Epizyme, Inc. | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200054635-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | EHMT2, BHMT, SHMT2 | PRCP 1258/4885CCR2 3505/4885CCR1 4021/4885 |
| US-20200113901-A1 | METHODS OF USING EHMT2 INHIBITORS | EHMT2, EHMT1, BHMT | PRCP 1989/4885CCR2 4678/4885CCR1 4656/4885 |
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | EHMT2, BHMT, SHMT2 | PRCP 1258/4885CCR2 3505/4885CCR1 4021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.